JP2023526044A5 - - Google Patents

Info

Publication number
JP2023526044A5
JP2023526044A5 JP2022568741A JP2022568741A JP2023526044A5 JP 2023526044 A5 JP2023526044 A5 JP 2023526044A5 JP 2022568741 A JP2022568741 A JP 2022568741A JP 2022568741 A JP2022568741 A JP 2022568741A JP 2023526044 A5 JP2023526044 A5 JP 2023526044A5
Authority
JP
Japan
Prior art keywords
icos
positive
foxp3
positive cells
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568741A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023526044A (ja
Filing date
Publication date
Priority claimed from GBGB2007099.1A external-priority patent/GB202007099D0/en
Application filed filed Critical
Publication of JP2023526044A publication Critical patent/JP2023526044A/ja
Publication of JP2023526044A5 publication Critical patent/JP2023526044A5/ja
Pending legal-status Critical Current

Links

JP2022568741A 2020-05-14 2021-05-13 免疫療法のための腫瘍バイオマーカー Pending JP2023526044A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2007099.1A GB202007099D0 (en) 2020-05-14 2020-05-14 Tumour biomarkers for immunotherapy
GB2007099.1 2020-05-14
PCT/EP2021/062778 WO2021229032A1 (en) 2020-05-14 2021-05-13 Tumour biomarkers for immunotherapy

Publications (2)

Publication Number Publication Date
JP2023526044A JP2023526044A (ja) 2023-06-20
JP2023526044A5 true JP2023526044A5 (enExample) 2024-05-21

Family

ID=71135069

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568741A Pending JP2023526044A (ja) 2020-05-14 2021-05-13 免疫療法のための腫瘍バイオマーカー

Country Status (12)

Country Link
US (1) US20230176060A1 (enExample)
EP (1) EP4150347A1 (enExample)
JP (1) JP2023526044A (enExample)
KR (1) KR20230009507A (enExample)
CN (1) CN117581101A (enExample)
AU (1) AU2021271120A1 (enExample)
BR (1) BR112022022250A2 (enExample)
CA (1) CA3178642A1 (enExample)
GB (1) GB202007099D0 (enExample)
IL (1) IL298164A (enExample)
MX (1) MX2022014247A (enExample)
WO (1) WO2021229032A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗fap-light融合蛋白及其用途
WO2025259871A1 (en) 2024-06-14 2025-12-18 Gilead Sciences, Inc. Anti-ccr8 antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1003648C2 (nl) 1996-07-19 1998-01-21 Carino Cornelis Sunderman Werkwijze en inrichting voor het bevorderen van de rookgasafvoer van een openhaardvuur.
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
CA2305350C (en) 1997-09-23 2015-04-07 Bundesrepublik Deutschland Letztvertreten Durch Den Direktor Des Robert-Koch-Instituts Costimulating polypeptide of t cells, monoclonal antibodies, and the preparation and use thereof
DE19821060A1 (de) 1997-09-23 1999-04-15 Bundesrepublik Deutschland Let Ko-stimulierendes Polypeptid von T-Zellen, monoklonale Antikörper sowie die Herstellung und deren Verwendung
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ailimに対するヒトモノクローナル抗体及びその医薬用途
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
EP1740617B1 (en) 2004-04-23 2013-10-16 BUNDESREPUBLIK DEUTSCHLAND letztvertreten durch das Robert Koch-Institut vertreten durch seinen Präsidenten Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
GB0521621D0 (en) 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
AU2008247382B2 (en) 2007-05-07 2014-06-05 Medimmune, Llc Anti-ICOS antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2627223T3 (es) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentación de agentes de unión
DE102007039429A1 (de) * 2007-08-21 2009-02-26 Imtm Gmbh Verfahren zur Aktivierung regulatorischer T-Zellen
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン,エルエルシー 抗体製剤
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
EP3147297B1 (en) 2011-03-31 2018-12-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies directed against icos and uses thereof
US20140170157A1 (en) 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
KR20140142719A (ko) * 2012-03-30 2014-12-12 제넨테크, 인크. 암의 치료를 위한 진단 방법 및 조성물
DE102012013637A1 (de) 2012-07-09 2014-01-09 Iwis Motorsysteme Gmbh & Co. Kg Triebstockplanetengetriebe
EP2872646B1 (en) 2012-07-12 2017-08-30 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
EP2880180B1 (en) 2012-08-06 2018-10-03 Institut National de la Sante et de la Recherche Medicale (INSERM) Methods and kits for screening patients with a cancer
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
EP2738557A1 (en) * 2012-12-03 2014-06-04 Université Libre de Bruxelles Organized immune response in cancer
EP3090066A4 (en) 2014-01-02 2017-08-30 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
US20160145344A1 (en) 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
JP2018503373A (ja) 2014-12-30 2018-02-08 ジェネンテック, インコーポレイテッド がんの予後診断及び治療のための方法及び組成物
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
RS60614B1 (sr) 2015-03-23 2020-08-31 Jounce Therapeutics Inc Antitela za icos
AU2016342269A1 (en) 2015-10-22 2018-03-29 Jounce Therapeutics, Inc. Gene signatures for determining icos expression
RU2769282C2 (ru) * 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
WO2018029474A2 (en) 2016-08-09 2018-02-15 Kymab Limited Anti-icos antibodies
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
US11858996B2 (en) * 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
JP7235508B2 (ja) * 2016-11-24 2023-03-08 第一三共株式会社 Pd-1免疫チェックポイント阻害剤による治療に対するがんの感受性を予測する方法
WO2018122245A1 (en) * 2016-12-28 2018-07-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting the survival time of patients suffering from cms3 colorectal cancer
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
WO2018225063A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer treatment with immune checkpoint inhibitors and kits therefor
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
CN112703012A (zh) 2018-05-14 2021-04-23 震动疗法公司 治疗癌症的方法
EP3849666B1 (en) 2018-09-14 2026-04-15 Université de Lausanne Methods for modulating regulatory t cells and inhibiting tumor growth
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen

Similar Documents

Publication Publication Date Title
JP2023526044A5 (enExample)
JP7564122B2 (ja) 光免疫療法のための方法および関連バイオマーカー
US11471519B2 (en) Methods of cancer treatment using tumor antigen-specific T cells
JP7032329B2 (ja) c-MAFの状態に基づく乳がんの治療的処置
CN112703012A (zh) 治疗癌症的方法
JP2020522508A (ja) 抗pd−1抗体を用いる腫瘍の治療方法
JP2013539468A5 (enExample)
KR20140009172A (ko) 종양 특이 항체 및 그 사용
JP2014523920A5 (enExample)
KR20240015054A (ko) 무세포 dna 단편화를 이용한 폐암 검출
WO2020086724A1 (en) Methods of treating tumor
CN110809628B (zh) 使用外周血t细胞的肿瘤细胞毒性活性作为指标预测肿瘤免疫疗法效果的方法
US20230383357A1 (en) Subject-specific treatments for venetoclax-resistant acute myeloid leukemia
CN112004945A (zh) 用于结肠癌检测和治疗监控的方法
JP2018532699A5 (enExample)
JP2017526916A (ja) 癌の診断
CN103842823B (zh) 用于胸膜间皮瘤患者的早期发现的分子标志物及其表达分析方法
JP2018516877A5 (enExample)
HRP20210858T1 (hr) Antitijelo za igf-1r i njegova upotreba u dijagnosticiranju karcinoma
JP7086607B2 (ja) Igf-1r抗体および癌の診断のためのその使用
CN115372618A (zh) 一种检测蛋白标志物水平的试剂在制备用于评估肿瘤治疗效果的诊断产品中的应用
JP2024540374A5 (enExample)
Zorniak Membrane proteomics of human glioblastoma stem-like cells
US20220349890A1 (en) A method for predicting risk of recurrence for early-stage colon cancer by measuring focal adhesion kinase
JPWO2017022634A1 (ja) グリオーマの予後、遠隔部再発リスク及び浸潤を判定する方法及びキット並びにグリオーマを処置するための医薬組成物